The in Vivo Toxicity of Hydroxyurea Depends on Its Direct Target Catalase

Hydroxyurea (HU) is a well tolerated ribonucleotide reductase inhibitor effective in HIV, sickle cell disease, and blood cancer therapy. Despite a positive initial response, however, most treated cancers eventually progress due to development of HU resistance. Although RNR properties influence HU re...

Descripción completa

Detalles Bibliográficos
Autores principales: Juul, Trine, Malolepszy, Anna, Dybkær, Karen, Kidmose, Rune, Rasmussen, Jan Trige, Andersen, Gregers Rom, Johnsen, Hans Erik, Jørgensen, Jan-Elo, Andersen, Stig Uggerhøj
Formato: Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2010
Materias:
Enzymology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898382/
https://www.ncbi.nlm.nih.gov/pubmed/20452979
http://dx.doi.org/10.1074/jbc.M110.103564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898382/
https://www.ncbi.nlm.nih.gov/pubmed/20452979
http://dx.doi.org/10.1074/jbc.M110.103564

Ejemplares similares